Loading
Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma.
Thierry Facon (Lille) was principal investigator of MAIA, the trial showing daratumumab plus lenalidomide-dexamethasone dramatically improves progression-free and overall survival in transplant-ineligible newly diagnosed myeloma, with median survival now beyond seven years, and of FIRST, which established continuous lenalidomide-dexamethasone in this population. He led the IFM frailty score work and co-leads the IMROZ isatuximab trial.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tags myeloma, trialist.
Shares CD38, Multiple myeloma and the tags myeloma, trialist.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares Multiple myeloma and the tags myeloma, trialist.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Monoclonal antibodies, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.
Shares CD38, Multiple myeloma and the tag myeloma.